FDA Leadership Turnover Raises concerns Over Agency Operations
A significant exodus of experienced personnel from teh Food and Drug Administration (FDA) has raised alarms about the agency’s ability to fulfill its core responsibilities, particularly the timely review of new drugs. This wave of departures follows reported cuts to the federal health workforce overseen by Robert F.Kennedy Jr. More than 1,000 individuals have reportedly accepted buyouts or early retirement, with many others actively seeking new employment.
The FDA’s drug center has been without a permanent director since january, when Dr. Patrizia Cavazzoni departed shortly before President Donald Trump’s inauguration.The turnover has extended to nearly all senior leadership positions within the agency in recent months,attributed to retirements,resignations,or administrative actions placing individuals on leave.
Historically, FDA center directors have maintained their roles for extended periods, frequently enough spanning years or even decades, and serving across different presidential administrations, nonetheless of party affiliation.
In May, Dr. Vinay Prasad, a vocal critic of the FDA’s COVID-19 response, was appointed to lead the agency’s vaccine center and also named FDA chief medical officer. Prasad joined the FDA after his predecessor, Dr. Peter Marks, the long-serving head of the vaccine center, was reportedly forced out in March. Additionally, the head of the FDA’s tobacco center resigned in April, and a permanent replacement has yet to be named.
The Associated Press health and Science Department is supported by the Howard Hughes Medical Institute’s Department of Science Education and the Robert Wood Johnson Foundation. The AP retains sole responsibility for all content.
